<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03188835</url>
  </required_header>
  <id_info>
    <org_study_id>2017-1459</org_study_id>
    <nct_id>NCT03188835</nct_id>
  </id_info>
  <brief_title>Effects of Fructose/Glucose-rich Diet on Brown Fat in Healthy Subjects (GB7)</brief_title>
  <acronym>GB7</acronym>
  <official_title>Brown Fat Energy Metabolism During Cold Exposure: Effects of Fructose- or Glucose-rich Diet in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Activating brown and beige adipose tissue (herein described as BAT) has been recently
      recognized as a potential means to increase energy expenditure and lower blood glucose,
      however, BAT activity appears to be reduced with obesity, aging or Type 2 Diabetes (T2D). BAT
      has the unique capability to burn large amounts of sugar and fat and effectively dissipate
      this energy as heat due to the expression of uncoupling protein 1 (UCP1) which is controlled
      by a thermogenic gene program of transcription factors, co-activators and protein kinases.
      Thus, enhancing the thermogenic gene program may be beneficial for treating obesity and T2D.
      Despite the importance of BAT in regulating metabolism our understanding of the factors which
      suppress its metabolic activity with obesity, aging and T2D are largely unknown. Recently, it
      was shown that peripheral serotonin, which is regulated by the tryptophan hydroxylase 1
      (Tph1), is a negative regulator of BAT metabolic activity. In addition to serotonin, other
      studies have indicated that pro-inflammatory stimuli may also inhibit BAT metabolic activity.
      These data suggest that reduced activation of BAT may be due to increases in peripheral
      serotonin and inflammation. Importantly, the gut microbiome has recently been recognized as
      an important regulator of serotonin and inflammatory pathways suggesting the observed effects
      of the microbiome on obesity, T2D may be mediated in part through reductions in BAT activity.

      One mechanism by which the environment may impact BAT activity and the thermogenic gene
      program over the last 3 decades involves changes in our food supply as result of changes in
      agricultural production (chlorpyrifos, glyphosphate) and the addition of food additives
      (fructose). These agents have been reported to alter inflammation, serotonin metabolism and
      the gut microbiome indicating a potential bimodal (direct and indirect via the microbiome)
      mechanism by which they may alter the thermogenic gene program and contribute to chronic
      metabolic disease. Thus, our overarching hypothesis is that environmental agents and
      additives related to food production may contribute to the reduced metabolic activity of BAT.
      The objective is to identify and characterize how food production agents and additives reduce
      the metabolic activity of BAT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each subject will follow 3 metabolic studies (A, B and C), each lasting 7.5h which includes a
      3h acute cold exposure.

      These studies will be almost identical: same perfusion of tracers, same number of Positron
      Emission Tomography (PET) acquisitions and same number of Magnetic Resonance Imaging (MRI)
      associated with Magnetic Resonance Spectroscopy (MRS) acquisitions .

      The difference will be in the diet ingested by the subjects two weeks before each metabolic
      study: during protocol A, the subjects will follow an isocaloric diet; during protocol B, the
      subjects will follow the same isocaloric diet supplemented with a daily beverage containing
      +25% of energy intake from fructose; and during protocol C, the subjects will follow the same
      isocaloric diet supplemented with a daily beverage containing +25% of energy intake from
      glucose.

      Stool samples will be collected for each metabolic study for microbiome flora and
      metabolites.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiome flora</measure>
    <time_frame>4 months</time_frame>
    <description>assessed from stool samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiome metabolites</measure>
    <time_frame>4 months</time_frame>
    <description>assessed from stool samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BAT oxidative metabolism</measure>
    <time_frame>4 months</time_frame>
    <description>will be determined using i.v. injection of 11C-acetate during dynamic PET/CT scanning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BAT triglyceride content</measure>
    <time_frame>4 months</time_frame>
    <description>will be determined by radiodensity or MRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BAT blood flow</measure>
    <time_frame>4 months</time_frame>
    <description>will be determined using i.v. injection of 11C-acetate during dynamic PET/CT scanning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAT net glucose uptake</measure>
    <time_frame>4 months</time_frame>
    <description>will be assessed using i.v. injection of 18FDG with sequential dynamic PET/CT scanning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole-body glucose partitioning</measure>
    <time_frame>4 months</time_frame>
    <description>will be assessed using i.v. injection of 18FDG with static PET/CT scanning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAT volume of metabolic activity</measure>
    <time_frame>4 months</time_frame>
    <description>will be determined using a total body CT (16 mA) followed by a PET acquisition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolites appearance rate</measure>
    <time_frame>12 months</time_frame>
    <description>will be determined by perfusion of stable isotope tracers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>energy metabolism (whole body production)</measure>
    <time_frame>4 months</time_frame>
    <description>by indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hormonal responses</measure>
    <time_frame>12 months</time_frame>
    <description>analysed by colorimetric and Elisa tests</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Isocaloric Diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Two weeks of isocaloric diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Two weeks of hypercaloric diet supplemented with fructose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Two weeks of hypercaloric diet supplemented with glucose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>A 2 weeks of hypercaloric diet supplemented with fructose or glucose</description>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cold exposure</intervention_name>
    <description>Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.</description>
    <arm_group_label>Isocaloric Diet</arm_group_label>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18FDG</intervention_name>
    <description>I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.</description>
    <arm_group_label>Isocaloric Diet</arm_group_label>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>11C-acetate</intervention_name>
    <description>i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning</description>
    <arm_group_label>Isocaloric Diet</arm_group_label>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[3-3H]-glucose</intervention_name>
    <description>i.v. administration of 1.5 uCi/min of [3-3H]-glucose</description>
    <arm_group_label>Isocaloric Diet</arm_group_label>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[U-13C]-palmitate</intervention_name>
    <description>i.v. administration of 0.08 umol/kg/min of [U-13C]-palmitate</description>
    <arm_group_label>Isocaloric Diet</arm_group_label>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2H-Glycerol</intervention_name>
    <description>i.v. administration of 0.05 µmol/kg/min of 2H-glycerol</description>
    <arm_group_label>Isocaloric Diet</arm_group_label>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI/MRS</intervention_name>
    <description>Visceral and cervico-thoracic MRI and MRS acquisition.</description>
    <arm_group_label>Isocaloric Diet</arm_group_label>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electromyogram (EMG)</intervention_name>
    <description>Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes</description>
    <arm_group_label>Isocaloric Diet</arm_group_label>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DXA</intervention_name>
    <description>Lean mass will be determined by dual-energy X-ray absorptiometry</description>
    <arm_group_label>Isocaloric Diet</arm_group_label>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Indirect calorimetry</intervention_name>
    <description>VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.</description>
    <arm_group_label>Isocaloric Diet</arm_group_label>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects: subjects with normal glucose tolerance determined according to an
             oral glucose tolerance test and with a BMI &lt; 27 kg/m2 without first degree of familial
             history of type 2 diabetes (parents, siblings).

        Exclusion Criteria:

          1. Plasma triglycerides &gt; 5.0 mmol/L at fasting;

          2. More than 2 alcohol consumption per day;

          3. More than 1 cigarette per day;

          4. History of total cholesterol level &gt; 7 mmol/L, of cardiovascular disease, hypertensive
             crisis;

          5. Treatment with fibrates, thiazolidinedione, insulin, beta-blockers or other drugs with
             effects on insulin resistance or lipid metabolism (exception for anti-hypertensive
             drugs, statins or metformin);

          6. Presence of a non-controlled thyroid disease, renal or hepatic disease, history of
             pancreatitis, bleeding diatheses, cardiovascular disease or any other serious medical
             conditions;

          7. History of serious gastrointestinal disorders (malabsorption, peptic ulcer,
             gastroesophageal reflux having required a surgery, etc.);

          8. Presence of a pacemaker;

          9. Have undergone of PET study or CT scan in the past year;

         10. Chronic administration of any medication;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André C. Carpentier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédérique Frisch</last_name>
    <phone>8193461110</phone>
    <phone_ext>12394</phone_ext>
    <email>frederique.frisch@usherbrooke.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de recherche du CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Frisch</last_name>
      <phone>8193461110</phone>
      <email>frederique.frisch@usherbrooke.ca</email>
    </contact>
    <investigator>
      <last_name>André C. Carpentier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2017</study_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>André Carpentier</investigator_full_name>
    <investigator_title>tenured professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

